Leukodystrophies are a heterogeneous class of genetic diseases affecting the white matter in the central nervous system with a broad range of clinical manifestations and a frequently progressive course. An interest in precision medicine has emerged over the last several decades, and biomedical research in leukodystrophies has made exciting advances along this front through therapeutic target discovery and novel disease model systems. In this review, we discuss current and emerging therapeutic approaches in leukodystrophies, including gene therapy, antisense oligonucleotide therapy, CRISPR/CAS-based gene editing, and cell and stem cell based therapies.
LattanziASalvagnoCMadernaC. Therapeutic benefit of lentiviral-mediated neonatal intracerebral gene therapy in a mouse model of globoid cell leukodystrophy. Hum Mol Genet. 2014;23(12):3250–3268.
8.
PowellSKKhanNParkerCL. Characterization of a novel adeno-associated viral vector with preferential oligodendrocyte tropism. Gene Ther. 2016;23(11):807–814.
9.
PapapetrouEPSchambachA. Gene insertion into genomic safe harbors for human gene therapy. Mol Ther. 2016;24(4):678–684.
10.
JansonCMcPheeSBilaniukL. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum Gene Ther. 2002;13(11):1391–1412.
11.
LeonePSheraDMcPheeSWJ. Long-term follow-up after gene therapy for Canavan disease. Sci Transl Med. 2012;4(165):165ra163.
12.
MendellJRAl-ZaidySShellR. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713–1722.
13.
GeorgiouESidiropoulouKRichterJ. Gene therapy targeting oligodendrocytes provides therapeutic benefit in a leukodystrophy model. Brain. 2017;140(3):599–616.
14.
RafiMARaoHZLuziPCurtisMTWengerDA. Extended normal life after AAVrh10-mediated gene therapy in the mouse model of Krabbe disease. Mol Ther. 2012;20(11):2031–2042.
15.
GodfreyCDesviatLRSmedsrødB. Delivery is key: lessons learnt from developing splice-switching antisense therapies. EMBO Mol Med. 2017;9(5):545–557.
16.
FinkelRSChiribogaCAVajsarJ. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016;388(10063):3017–3026.
17.
FinkelRSMercuriEDarrasBT. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723–1732.
18.
HagemannTLPowersBMazurC. Antisense suppression of glial fibrillary acidic protein as a treatment for Alexander disease. Ann Neurol. 2018;83(1):27–39.
19.
LiangPZhangXChenYHuangJ. Developmental history and application of CRISPR in human disease. J Gene Med. 2017;19(6-7):e2963.
20.
YinHXueWChenS. Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. Nat Biotechnol. 2014;32(6):551–553.
21.
LongCAmoasiiLMireaultAA. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science. 2016;351(6271):400–403.
22.
XieFYeLChangJC. Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac. Genome Res. 2014;24(9):1526–1533.
23.
LiHLFujimotoNSasakawaN. Precise correction of the dystrophin gene in Duchenne muscular dystrophy patient induced pluripotent stem cells by TALEN and CRISPR-Cas9. Stem Cell Rep. 2015;4(1):143–154.
24.
KrivitWShapiroEGPetersC. Hematopoietic stem-cell transplantation in globoid-cell leukodystrophy. N Engl J Med. 1998;338(16):1119–1126.
25.
KrivitWSungJHShapiroEGLockmanLA. Microglia: the effector cell for reconstitution of the central nervous system following bone marrow transplantation for lysosomal and peroxisomal storage diseases. Cell Transplant. 1995;4(4):385–392.
26.
HoogerbruggePMSuzukiKSuzukiK. Donor-derived cells in the central nervous system of twitcher mice after bone marrow transplantation. Science. 1988;239(4843):1035–1038.
27.
RestonJTUhlSTreadwellJRNashRASchoellesK. Autologous hematopoietic cell transplantation for multiple sclerosis: a systematic review. Mult Scler J. 2010;17(2):204–213.
28.
ShouvalRFurieNRaananiPNaglerAGafter-GviliA. Autologous hematopoietic stem cell transplantation for systemic sclerosis: a systematic review and meta-analysis. Biol Blood Marrow Transplant. 2018;24(5):937–944.
29.
SadakKTSmithARBhatiaM. Long-term effects of hematopoietic stem cell transplantation for sickle cell disease. In: MeierRAbrahamAFasanoRM, eds. Sickle Cell Disease and Hematopoietic Stem Cell Transplantation. Cham, Switzerland: Springer; 2017:235–249.
30.
AnthonySAStephenFJ. Allogeneic and autologous hematopoietic stem cell transplantation for acute lymphoblastic leukemia and acute myelogenous leukemia in the adult. In: HoAHassRChamplinR, eds. Hematopoietic Stem Cell Transplantation. New York: Marcel Dekker; 2008:57–82.
BattiwallaMHashmiSMajhailNPavleticSSavaniBNShelburneN. National institutes of health hematopoietic cell transplantation late effects initiative: developing recommendations to improve survivorship and long-term outcomes. Biol Blood Marrow Transplant. 2017;23(1):6–9.
33.
EichlerFDuncanCMusolinoPL. Hematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy. N Engl J Med. 2017;377(17):1630–1638.
34.
MitchellRNivison-SmithIAnazodoA. Outcomes of haematopoietic stem cell transplantation for inherited metabolic disorders: a report from the Australian and New Zealand Children’s Haematology Oncology Group and the Australasian Bone Marrow Transplant Recipient Registry. Pediatr Transplant. 2013;17(6):582–588.
35.
BhatiaSArmenianSHLandierW. How I monitor long-term and late effects after blood or marrow transplantation. Blood. 2017;130(11):1302–1314.
36.
BoelensJJPrasadVKTolarJWynnRFPetersC. Current international perspectives on hematopoietic stem cell transplantation for inherited metabolic disorders. Pediatr Clin North Am. 2010;57(1):123–145.
PetersCCharnasLRTanY. Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999. Blood. 2004;104(3):881–888.
39.
MahmoodARaymondGVDubeyPPetersCMoserHW. Survival analysis of haematopoietic cell transplantation for childhood cerebral X-linked adrenoleukodystrophy: a comparison study. Lancet Neurol. 2007;6(8):687–692.
40.
ShapiroEKrivitWLockmanL. Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy. Lancet. 2000;356(9231):713–718.
41.
PierpontEIEisengartJBShanleyR. Neurocognitive trajectory of boys who received a hematopoietic stem cell transplant at an early stage of childhood cerebral adrenoleukodystrophy. JAMA Neurol. 2017;74(6):710.
42.
KemperARBroscoJComeauAM. Newborn screening for X-linked adrenoleukodystrophy: evidence summary and advisory committee recommendation. Genet Med. 2017;19(1):121–126.
43.
DuffnerPKCavinessVSErbeRW. The long-term outcomes of presymptomatic infants transplanted for Krabbe disease: report of the workshop held on July 11 and 12, 2008, Holiday Valley, New York. Genet Med. 2009;11(6):450–454.
44.
GuptaNHenryRGStroberJ. Neural stem cell engraftment and myelination in the human brain. Sci Transl Med. 2012;4(155):155ra137–155ra137.
45.
KeefeRSEKraemerHCEpsteinRS. Defining a clinically meaningful effect for the design and interpretation of randomized controlled trials. Innov Clin Neurosci. 2013;10(5-6)(suppl A):4S–19S.
46.
FrankLBaschESelbyJV. The PCORI perspective on patient-centered outcomes research. JAMA. 2014;312(15):1513.
47.
KellerJLWangJIKangJY. Strength: a relevant link to functional performance in the neurodegenerative disease of adrenomyeloneuropathy. Neurorehabil Neural Repair. 2012;26(9):1080–1088.
48.
TurkBRTheisenBENemethCL. Antioxidant capacity and superoxide dismutase activity in adrenoleukodystrophy. JAMA Neurol. 2017;74(5):519–524.
49.
CastellanoAPapinuttoNCadioliM. Quantitative MRI of the spinal cord and brain in adrenomyeloneuropathy: in vivo assessment of structural changes. Brain. 2016;139(pt 6):1735–1746.
50.
HubbardWCMoserABLiuAC. Newborn screening for X-linked adrenoleukodystrophy (X-ALD): validation of a combined liquid chromatography-tandem mass spectrometric (LC-MS/MS) method. Mol Genet Metab. 2009;97(3):212–220.
51.
KwonJMMaternDKurtzbergJ. Consensus guidelines for newborn screening, diagnosis and treatment of infantile Krabbe disease. Orphanet J Rare Dis. 2018;13(1):30.
52.
VogelBHBradleySEAdamsDJ. Newborn screening for X-linked adrenoleukodystrophy in New York State: diagnostic protocol, surveillance protocol and treatment guidelines. Mol Genet Metab. 2015;114(4):599–603.
53.
BurgartAMMagnusDTaborHK. Ethical challenges confronted when providing nusinersen treatment for spinal muscular atrophy. JAMA Pediatr. 2018;172(2):188–192.
54.
SharrocksKSpicerJCamidgeDRPapaS. The impact of socioeconomic status on access to cancer clinical trials. Br J Cancer. 2014;111(9):1684–1687.
55.
PapaS. Barriers to cancer clinical trials: the role of socioeconomic status/Role of SES in Determining Access to Clinical Trials and Treatment. J Geriatr Oncol. 2013;4:S9.
56.
AdangLASherbiniOBallL. Revised consensus statement on the preventive and symptomatic care of patients with leukodystrophies. Mol Genet Metab. 2017;122(1-2):18–32.
